Other shareholders also are concerned about management's moves, sources familiar with the matter said on Tuesday, adding that several large owners had supported Elliott's call for a market check to identify meaningful interest to buy the company.For Elliott, the Portola deal was only the latest in a string of missteps that include the purchase of Achillion Pharmaceuticals for $930 million, as the company tries to diversify its revenue base away from its bestselling drugs for rare blood disorders.